Dexcom (DXCM) investor relations material

Strategic priorities and growth drivers

• Focus on expanding leadership in glucose sensing for all diabetes patients and broader metabolic health, with a goal to become the premier solution and set the standard for customer experience.

• Emphasis on customer experience, scalable innovation, and international market share growth, including tailored product portfolios and direct market entry in key countries such as India, Brazil, and Mexico within two years.

• Organizational changes include new leadership roles, hiring a Chief Product Officer, and board governance enhancements with new independent directors and committee updates.

• Integration of manufacturing, supply chain, and quality under a single executive leader to support high-volume operations and efficiency.

• Enhanced governance with new Operations and Innovation Committees and collaboration with Elliott Management.

Product innovation and clinical evidence

• Launch of G7 15 Day sensor with improved accuracy, adhesive, and extended wear time; rapid U.S. adoption and international rollout planned.

• G8 platform to launch by late 2027/early 2028, offering adaptive sensing, multi-analyte capabilities, and a 50% smaller form factor.

• Expansion of product portfolio with Dexcom Flex and Stelo for international and wellness markets, with launches in Germany and other countries in late 2026/early 2027.

• Smart Basal and Smart Bolus software solutions, direct EHR integration, and digital therapeutics to improve insulin dosing, patient outcomes, and clinician workflows.

• Ongoing clinical trials (CONNECT) and real-world data support expanded CGM coverage, especially for type 2 non-insulin users, with demonstrated reductions in A1C, cardiovascular risk, and healthcare costs.

Commercial execution and market expansion

• U.S. sales force expanded by 40% to target primary care and prepare for coverage expansion.

• Anticipates Medicare coverage for all people with diabetes by mid-2027, expected to double addressable market and significantly expand US access.

• Personalized patient engagement strategies leverage Stelo app insights across product lines.

• International strategy targets market access expansion in core geographies, new direct transitions, and focus on top 10 international markets with significant opportunity in type 2 diabetes penetration.

• Plans to enter India, Brazil, and Mexico within two years to further expand international presence.